Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.…
Insight Molecular Diagnostics (IMDX) Stock Sees Fair Value Cut As FDA Questions Cloud Analyst Views
Insight Molecular Diagnostics (NASDAQ: IMDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 1.970 USD on 20 November 2026, down 68.4% over 52 weeks. Its 52-week range is 1.500 USD to 8.510 USD: the price is 76.9% below the high and 31.3% above the low.
Its market capitalisation is 80.88M USD.
Insight Molecular Diagnostics reports return on equity of 159.6% and revenue up 115.0% year over year.
It holds more cash than debt, a net cash position of 8.83M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 7.250 USD is 268.0% above the current price. The next earnings report is expected on 31 March 2027.